Penetrating Keratoplasty (Optical) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Penetrating keratoplasty (PK) — commonly known as a full-thickness corneal transplant — has been performed for over a century and remains one of the most successful solid tissue transplants in medicine, with reported graft survival rates of 73–78% at five years for the most favourable indications such as keratoconus. In PK, the patient's diseased cornea (the transparent dome-shaped front window of the eye) is completely removed and replaced with a full-thickness donor corneal button of matching diameter, sutured in place with interrupted or continuous 10-0 nylon sutures.

The cornea comprises five anatomically distinct layers: the epithelium, Bowman's layer, the stroma (making up approximately 90% of corneal thickness), Descemet's membrane, and the endothelium. The endothelium — a single layer of hexagonal cells — is responsible for maintaining corneal transparency by actively pumping fluid out of the stroma. Unlike most body cells, corneal endothelial cells do not regenerate; their loss leads to corneal oedema and blindness.

A major paradigm shift has occurred in corneal surgery over the past two decades. Rather than replacing the entire cornea when only one or two layers are diseased, modern selective (lamellar) transplantation techniques target only the affected layers: Deep Anterior Lamellar Keratoplasty (DALK) replaces the anterior stroma and Bowman's layer while preserving the host endothelium; Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) and Descemet Membrane Endothelial Keratoplasty (DMEK) replace only the diseased endothelium-Descemet membrane complex. These selective approaches offer faster visual recovery, lower rejection risk, and superior long-term outcomes compared with PK in appropriately selected patients.

Corneal transplantation addresses a spectrum of conditions causing corneal blindness through disease of specific corneal layers. Matching the transplant technique to the diseased layer is central to modern corneal surgery:

• Fuchs Endothelial Corneal Dystrophy (FECD): The most common indication for endothelial keratoplasty in the developed world. FECD is a progressive bilateral condition in which abnormal collagen deposits (guttata) accumulate beneath the endothelium, leading to endothelial cell loss, corneal oedema ("corneal decompensation"), and progressive visual loss. DMEK is the preferred procedure for FECD, offering superior visual outcomes (75–80% of eyes achieving 20/25 or better), lowest rejection rates (less than 1% per year), and fastest recovery compared with DSAEK or PK.
• Keratoconus: A progressive bilateral ectatic dystrophy in which the cornea assumes an irregular cone shape due to collagen weakness, causing progressive myopia, irregular astigmatism, and eventually corneal scarring in advanced cases. Crosslinking halts progression; DALK is preferred for advanced keratoconus requiring transplant, as it preserves the healthy host endothelium and eliminates the risk of endothelial rejection. PK remains indicated for keratoconus with stromal scarring extending to Descemet's membrane or failed DALK conversion.
• Herpetic Corneal Scarring: Recurrent herpes simplex keratitis causes progressive stromal scarring and neovascularisation, significantly increasing the risk of graft rejection post-PK. These "high-risk" vascularised host beds require intensive post-operative immunosuppression and antiviral prophylaxis (oral aciclovir 400 mg twice daily) continued long-term after PK.
• Bullous Keratopathy: Corneal endothelial decompensation following cataract surgery (pseudophakic bullous keratopathy) or Fuchs dystrophy results in painful epithelial bullae and reduced vision. DMEK or DSAEK are the procedures of choice.
• Corneal Dystrophies: Granular, macular, and lattice dystrophies cause progressive stromal opacity requiring PK or DALK depending on depth of stromal involvement. Recurrence of dystrophy within the graft occurs in some cases, particularly granular and lattice dystrophies.
• Chemical and Thermal Burns: Severe ocular surface burns with corneal scarring and limbal stem cell deficiency may require staged reconstruction including limbal stem cell transplantation before or concurrent with penetrating keratoplasty.

Eligibility for corneal transplantation and the selection of the optimal transplant technique are determined through comprehensive ophthalmic assessment, corneal imaging, and eye bank consultation:

• Functional visual impairment: Surgery is generally indicated when corneal disease causes best-corrected visual acuity that cannot be adequately rehabilitated with spectacles or rigid contact lenses, typically when visual acuity is 6/18 (20/60) or worse and is primarily attributable to corneal pathology rather than posterior segment or optic nerve disease.
• Anterior segment assessment: Slit-lamp examination documents the extent, depth, and vascularisation of corneal pathology. Specular microscopy quantifies host endothelial cell density. Corneal topography (Pentacam, Orbscan) maps corneal curvature and thickness, essential for keratoconus staging and surgical planning.
• Posterior segment evaluation: A corneal transplant cannot restore vision if there is significant co-existing macular degeneration, glaucomatous optic nerve damage, or amblyopia. Pre-operative potential acuity testing (laser interferometry or Potential Acuity Meter) helps predict post-operative visual potential through a hazy cornea.
• Donor tissue availability: Eye bank corneas must meet minimum quality standards — endothelial cell count greater than 2,000 cells/mm² (ideally greater than 2,500 for DMEK), absence of endothelial disease, and negative donor serology for HIV, hepatitis B/C, and syphilis. DMEK requires particularly high-quality donor tissue with meticulous pre-stripping technique; less than 20–30% of eye bank corneas are suitable for DMEK.
• High-risk host beds: Corneas with active or recent herpetic infection, corneal vascularisation in two or more quadrants, previous failed grafts, or limbal stem cell deficiency are classified as "high-risk." These patients have significantly lower graft survival rates and may require systemic immunosuppression (mycophenolate mofetil, tacrolimus) in addition to topical steroids post-operatively.
• Patient compliance: The post-operative regimen — particularly the prolonged topical steroid taper and vigilance for graft rejection symptoms — requires a motivated and compliant patient with reliable access to ophthalmic follow-up.

The choice of corneal transplantation technique is guided by the anatomical layer of corneal disease. The following procedures represent the current spectrum of corneal surgical options:

• Penetrating Keratoplasty (PK): Full-thickness donor corneal button (typically 7.5–8.5 mm diameter) is trephinated from the donor and recipient cornea using a motorised or hand-held trephine (Hessburg-Barron vacuum trephine). The graft is sutured in place with sixteen interrupted 10-0 nylon sutures or a combination of interrupted and single running sutures. PK remains indicated when disease affects all corneal layers (full-thickness scarring, failed DALK, or conditions where lamellar techniques are not feasible). Modern refractive PK uses femtosecond laser cutting (zigzag, mushroom, or top-hat profiles) to create improved wound architecture and theoretically reduce post-keratoplasty astigmatism.
• Deep Anterior Lamellar Keratoplasty (DALK): The diseased anterior stroma is removed while the patient's own Descemet's membrane and endothelium are preserved. The gold-standard technique is big-bubble DALK (Anwar and Teichmann technique), in which air is injected into the deep stroma to create a large pneumatic dissection plane between the stroma and Descemet's membrane, facilitating complete stromal removal. Advantages over PK include no endothelial rejection risk, stronger wound (full-thickness sutures avoided), and preservation of natural anterior biomechanics. Failure requiring conversion to PK occurs in approximately 10–15% of cases when the bubble cannot be formed or perforation of Descemet's membrane occurs.
• DSAEK (Descemet Stripping Automated Endothelial Keratoplasty): Replaces the diseased endothelium-Descemet membrane complex together with a thin layer of donor posterior stroma. The graft (typically 100–180 microns thick) is folded and inserted through a 4–5 mm incision, unfolded in the anterior chamber, and supported by an air bubble for 60 minutes. DSAEK is technically more forgiving than DMEK with lower primary graft failure rates, making it the preferred endothelial transplant in complex anterior segment anatomy (iris-fixated IOL, tube shunts, trabeculectomy blebs).
• DMEK (Descemet Membrane Endothelial Keratoplasty): Transplants only the donor Descemet's membrane and endothelium — a graft of approximately 10–15 microns thickness — without any donor stromal tissue. DMEK consistently achieves the best visual outcomes of all endothelial keratoplasty techniques (75–80% of eyes reach 20/25 or better at 1 year) with the lowest immunological rejection rate (less than 1% per year). The principal challenge is graft handling — the Descemet membrane scrolls spontaneously and requires meticulous technique for loading, insertion, and unscrolling within the eye.

Corneal transplantation, when indicated and performed at an experienced corneal surgical centre, offers substantial and well-documented benefits for visual function and quality of life:

• Restoration of vision: Penetrating keratoplasty for keratoconus achieves best-corrected visual acuity of 20/40 or better in approximately 80–90% of cases at five years. DMEK for Fuchs dystrophy achieves 20/25 or better in 75–80% of eyes at one year — representing remarkable visual rehabilitation from the profound glare, halos, and visual blur of advanced endothelial decompensation.
• Avoidance of rejection with lamellar techniques: DALK, by preserving the host endothelium, completely eliminates the risk of endothelial graft rejection — the most common cause of PK failure. DMEK carries the lowest rejection rate of any transplant technique at less than 1% per year, compared with 5–10% per year for PK in standard-risk corneas.
• Faster visual recovery: DMEK patients typically achieve functional vision within 1–4 weeks of surgery compared with 12–18 months for suture-dependent PK (where suture removal and astigmatism management are rate-limiting steps). This represents a transformative improvement in the patient experience of corneal transplantation.
• Structural integrity: PK with full-thickness sutures creates a closed-globe wound with theoretically higher susceptibility to traumatic wound dehiscence compared with lamellar techniques. DMEK and DSAEK, inserted through a small self-sealing incision, result in a structurally stronger eye post-operatively.
• Reduced systemic immunosuppression: Unlike solid organ transplants, corneal grafts are largely immune-privileged due to the avascular and lymphatic-free environment of the cornea. Topical steroid eye drops are typically sufficient immunosuppression for standard-risk cases, avoiding the systemic toxicities of oral immunosuppressants.
• Long-term graft survival: The Australian Corneal Graft Registry reports 10-year PK survival rates of approximately 69% for keratoconus — the most favourable indication — with graft survival declining for higher-risk indications. DSAEK and DMEK demonstrate excellent medium-term survival rates though longer-term registry data is still accumulating for these newer techniques.

Corneal transplantation is a technically demanding microsurgical procedure with well-characterised intraoperative and post-operative risks that must be discussed with patients before surgery:

• Graft rejection: The most important cause of late graft failure in PK. Endothelial rejection is characterised by a line of keratic precipitates on the donor endothelium (Khodadoust line), corneal oedema, and reduced vision — constituting an ophthalmic emergency requiring immediate intensive topical and systemic steroid treatment to reverse. Risk factors include corneal vascularisation, previous failed grafts, large graft diameter, and poor topical steroid compliance. DMEK has near-eliminated endothelial rejection risk.
• Primary graft failure: Failure of the donor endothelium to function from the outset, resulting in persistent corneal oedema requiring re-grafting. Risk factors include suboptimal donor tissue quality (low endothelial cell count) and difficult surgical manipulation during insertion. Rates of less than 1% for PK and 1–5% for DMEK (related to handling complexity) are reported at experienced centres.
• Post-keratoplasty astigmatism: High irregular astigmatism — often 4–6 dioptres or more — is the principal factor limiting best-corrected visual acuity after PK and the reason that post-PK visual rehabilitation takes 12–18 months. Management options include selective suture removal, wedge resection, astigmatic keratotomy, and laser refractive surgery (LASIK or PRK) once the refraction has stabilised.
• Intraoperative complications: Expulsive suprachoroidal haemorrhage — sudden haemorrhage into the suprachoroidal space when the eye is open — is a rare (less than 0.5%) but potentially catastrophic complication of PK, risking permanent vision loss. Lens or iris damage during trephination and wound leak post-operatively are additional recognised risks.
• DMEK-specific complications: Graft detachment requiring rebubbling (air injection to reattach the Descemet graft) occurs in 10–35% of DMEK cases — most within the first 2 weeks — and usually resolves with repeat air injection without long-term sequelae. Pupillary block by the gas bubble requires preventive measures (peripheral iridotomy, postural positioning).
• Infection: Microbial keratitis in the donor graft, endophthalmitis, and reactivation of donor-derived latent viral infections (CMV endotheliitis — increasingly recognised) are uncommon but potentially graft-threatening complications.

Post-operative follow-up after corneal transplantation is intensive in the first weeks and then structured as a long-term surveillance programme, given that graft rejection can occur at any point after surgery:

• Immediate post-operative care (first week): Following DMEK and DSAEK, the patient is instructed to lie supine for the first 24–48 hours to keep the air or gas bubble in contact with the graft. Eye drops — antibiotic (chloramphenicol or moxifloxacin) and steroid (prednisolone acetate 1%) — are commenced immediately post-operatively. Intraocular pressure is checked the following morning, as the gas bubble can temporarily raise pressure.
• Topical steroid taper after PK: Prednisolone acetate 1% eye drops are prescribed at high frequency (hourly initially, reducing over weeks) and then tapered slowly over 12–18 months or maintained indefinitely at low doses (once or twice daily) in high-risk cases. Premature steroid withdrawal is the most common cause of preventable acute graft rejection.
• Rejection surveillance education: All patients are specifically counselled on the acute symptoms of graft rejection — sudden reduction in vision, light sensitivity, redness, and eye pain — and instructed to attend the eye unit immediately if these occur. The proverb used in corneal clinics is the "RSVP sign" — Redness, Sensitivity to light, Vision decrease, Pain — to aid patient recall.
• Suture management after PK: Interrupted 10-0 nylon sutures are removed selectively at the slit lamp from 12 months post-operatively, guided by corneal topography to reduce astigmatism. Running sutures may remain in place for 2–3 years or longer if the refraction is stable and the suture is intact.
• Post-keratoplasty astigmatism management: High irregular astigmatism persisting after suture removal requires rigid gas-permeable (RGP) contact lens fitting — the most reliable optical correction for irregular astigmatism post-PK. The PEARL (Post-keratoplasty Astigmatism Reduction by Laser) protocol uses toric IOL implantation or laser refractive surgery to reduce regular astigmatism once manifest refraction has stabilised for at least 6–12 months.
• Long-term endothelial cell monitoring: Specular microscopy is performed annually to track donor endothelial cell density. Endothelial cell loss of approximately 5–10% per year in the first few years after PK is normal; accelerated loss suggests early rejection or graft decompensation requiring urgent intervention.

The cost of corneal transplantation is determined by the type of procedure, donor tissue sourcing, hospital setting, and post-operative follow-up requirements. Key cost drivers include:

• Donor tissue procurement: Eye bank corneas are a significant cost component. Processing, endothelial cell assessment, serological testing, and storage of a single donor cornea may cost USD $2,000–$4,000 in the USA, with additional pre-stripping and quality assessment for DMEK adding further cost. In the UK, NHS Blood and Transplant provides tissue at lower cost within the public healthcare system.
• Surgical technique: PK is technically straightforward and cost-efficient in terms of surgical time. DMEK, while superior in outcomes, requires specialised training, costly pre-cut tissue preparation, and a higher rebubbling rate that may add theatre costs. Overall procedure costs range from USD $5,000–$15,000 in the USA at ambulatory surgical centres.
• Post-operative care duration: Corneal transplantation requires prolonged post-operative ophthalmic care — steroid eye drops for 12–18 months, multiple slit-lamp review appointments, specular microscopy, and corneal topography over several years. This ongoing care cost can equal or exceed the initial surgical cost in private healthcare systems.
• Contact lens fitting for astigmatism: Post-PK patients frequently require rigid gas-permeable contact lenses for visual rehabilitation — initial fitting, ongoing lens wear, and replacement lenses add to the total lifetime cost of the procedure.
• Medical tourism considerations: Corneal transplantation is increasingly available at specialist eye hospitals in India (L.V. Prasad Eye Institute, Sankara Nethralaya, Aravind Eye Hospital), Thailand, Turkey, and South Korea at significantly lower costs than the USA or Western Europe. Eye banking infrastructure in India and Thailand is well-developed, with high-quality donor tissue available. International patients should confirm that the treating centre has eye bank accreditation equivalent to Eye Bank Association of America (EBAA) or European Eye Bank Association (EEBA) standards before proceeding.
• Repeat grafting: Failed grafts requiring re-grafting substantially increase the total lifetime cost of corneal blindness management, reinforcing the value of initial expert surgical management to maximise primary graft survival.

Corneal transplantation is not always the first or only treatment option for corneal disease. A range of conservative, contact lens, and surgical alternatives should be considered before proceeding to transplantation:

• Rigid gas-permeable (RGP) contact lenses for keratoconus: Custom-fitted RGP lenses vault over the irregular cone surface and neutralise keratoconus-induced irregular astigmatism, achieving excellent functional vision in the majority of keratoconus patients without requiring surgery. Scleral contact lenses — which rest on the sclera rather than the cornea — are particularly well-tolerated in advanced keratoconus and may defer or avoid the need for transplantation in many patients.
• Corneal collagen crosslinking (CXL): Riboflavin-ultraviolet-A corneal crosslinking (Dresden protocol or accelerated variants) stiffens collagen bonds within the anterior stroma, halting the progression of keratoconus and ectatic dystrophies. CXL does not reverse existing corneal irregularity but prevents further deterioration, potentially deferring transplantation by years or indefinitely in patients treated early. It is now first-line treatment for progressive keratoconus.
• Intrastromal corneal ring segments (ICRS): Polymethylmethacrylate ring segments (Intacs, Keraring) implanted within the mid-peripheral corneal stroma can regularise keratoconus-induced irregular astigmatism and improve best-corrected visual acuity and contact lens tolerance. ICRS is a reversible procedure that may delay transplantation in moderate keratoconus.
• Topical drops for early Fuchs dystrophy: Hypertonic saline eye drops (5% sodium chloride) reduce corneal epithelial oedema in early Fuchs dystrophy and may provide symptomatic relief of morning blur, though they do not halt endothelial cell loss or disease progression.
• Keratoprosthesis (KPro): For patients with repeated graft failures or extremely high-risk corneal beds — such as those with severe ocular surface disease, alkali burns, or autoimmune conditions — the Boston Keratoprosthesis (type I or type II) represents an artificial corneal implant that can restore vision when conventional corneal transplantation has failed or is contraindicated. KPro carries a significant long-term complication rate (infection, glaucoma, device extrusion) and requires lifelong specialist care.
• Femtosecond laser-assisted keratoplasty: Femtosecond laser-cut PK profiles (zigzag, mushroom, top-hat) create interlocking donor-host wound architecture that may accelerate visual rehabilitation and improve wound strength compared with conventional mechanical trephination, though comparative randomised data on visual outcomes remain limited.